All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
TCR NKT15 "AAA" is derived from NKT15 TCR, which contains a triple alanine mutant in the 98-RDR-100 sequence (encoded by Dβ-N), which is highly solvent accessible and, as such, their mutation is not predicted to affect the conformation of the CDR3α loop. SPR-binding studies of this "AAA" mutant NKT15 TCR revealed its affinity for both human and mouse CD1d/α-GalCer was comparable to the wild-type NKT15, indicating these three exposed residues are not critical to the affinity of the interaction. In addition, this hybrid TCR inhibited staining of mouse NKT cells by mCD1d/α-GalCer tetramers at the same concentration as NKT12 and NKT15 TCRs.
There are currently no customer reviews or questions for Human anti-α-GalCer T cell receptor (NKT15 AAA), pCDTCR1 (TCR-YC1421). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION